Navigation Links
ChemDiv and Avineuro Extend Collaboration on Alzheimer's Disease and Schizophrenia
Date:11/21/2008

SAN DIEGO, Nov. 21 /PRNewswire/ -- ChemDiv Inc. and Avineuro Pharmaceuticals Inc. have extended the term of their research and development collaboration including formulation, safety and early clinical development studies in areas of neurodegenerative and psychiatric disorders. R&D services will be provided by Chemical Diversity Research Institute, ChemDiv's research subsidiary based in Moscow. The new agreement provides for research funding of clinical candidate compounds to POC. Avineuro is responsible for further clinical development and commercialization of drug candidates AVN101, AVN211, and additional compounds that may be nominated for development from the ongoing research and discovery under the agreement. In September, ChemDiv entered into an out-licensing and collaboration agreement with Avineuro to develop multiple compounds for Alzheimer Disease and schizophrenia. Under the agreement, Avineuro obtained exclusive worldwide rights to clinical development candidates AVN101, AVN211, and lead compounds in various stages of pre-clinical development. ChemDiv will provide pre-clinical development services to nominate additional backup leads and candidates for Avineuro.

About Avineuro Pharmaceuticals, Inc.:

Avineuro Pharmaceuticals, Inc. discovers and develops novel small molecules for unmet medical needs in neurology and psychiatry. Founded in August 2008 and headquartered in San Diego, California, Avineuro is managed by seasoned professionals experienced in drug discovery and development. By acquiring lead compounds through collaborations and partnerships, Avineuro plans to develop novel products and extend the reach of marketed compounds for indications with a significant commercial potential. Avineuro emphasizes a rational approach that combines modern medicinal chemistry with streamlined pre-clinical and clinical development studies, thus allowing a fast transition to proof-of-concept product candidates.

About ChemDiv, Inc.

ChemDiv, Inc. is a global chemistry-driven contract research organization accelerating discovery and development of novel therapies through comprehensive Discovery outSource(TM) services, including pre-clinical development, discovery biology, medicinal and synthetic chemistry.


'/>"/>
SOURCE ChemDiv, Inc.; Avineuro Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ChemDiv and Achaogen Enter Into a Discovery Collaboration
2. Syndexa Pharmaceuticals Corporation and ChemDiv, Inc. Announce Discovery Collaboration
3. Roche Extends Tender Offer for Ventana
4. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
5. ARUP Laboratories and Premier Extend Contract for Reference Laboratory Testing Services
6. Discussions With FDA on Pixantrone EXTEND (PIX301) Trial Provide Path for NDA Submission
7. MichBio Announces Expo Tours; Extends Deadline for Innovator Showcase Applications
8. ChemAxon and Agilent Technologies Sign Agreement Extending JChem Integration With Kalabie Electronic Lab Notebook
9. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
10. Dey L.P. and Critical Therapeutics Launch Twice-Daily ZYFLO CR(TM) (Zileuton) Extended-Release Tablets for the Chronic Treatment of Asthma
11. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... ... , ... Any expert in stem cell research or stem cell medicine knows ... a century. Despite their essential roles in human health and regenerative medicine, adult ... developed for this purpose also tag other, more abundant, non-stem tissue cells ( See ...
(Date:8/15/2017)... ... August 15, 2017 , ... JULABO USA ... responsive, the new website makes it easy to navigate through the site whether ... now find detailed product information, educational industry content and visit the company’s social ...
(Date:8/11/2017)... Md. , Aug. 11, 2017 /PRNewswire/ ... a New York Times article regarding the ... billion, according to Kalorama Information.  The article, ... App for That"  used information from ... Patient Monitoring & Telemedicine Market  (Sleep, Diabetes, ...
(Date:8/10/2017)... ... August 09, 2017 , ... ... agriculture industry reach its ideal customers with the right message. Their effective, cutting-edge ... a Midwest company, we realize how crucial the agriculture industry is,” said David ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 No two ... researchers at the New York University Tandon School ... Engineering have found that partial similarities between prints ... used in mobile phones and other electronic devices ... The vulnerability lies in the fact that ...
(Date:4/5/2017)... -- Today HYPR Corp. , leading innovator in ... the HYPR platform is officially FIDO® Certified . ... that empowers biometric authentication across Fortune 500 enterprises and ... 15 million users across the financial services industry, however ... suites and physical access represent a growing portion of ...
(Date:3/30/2017)... , March 30, 2017  On April 6-7, ... Hack the Genome hackathon at Microsoft,s headquarters ... two-day competition will focus on developing health and wellness ... Hack the Genome is the first ... tremendous. The world,s largest companies in the genomics, tech ...
Breaking Biology News(10 mins):